413
Views
2
CrossRef citations to date
0
Altmetric
Articles

Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting

, , , , , & show all
Pages 2063-2067 | Received 27 Mar 2021, Accepted 02 Apr 2021, Published online: 21 Oct 2021

References

  • Muralidharan V, Pathmarajah P, Peterknecht E, et al. Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: a multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. Dermatol Ther. 2020;34(1):e14643.
  • Dunstan RW, Salte KM, Todorović V, et al. Histologic progression of acne inversa/hidradenitis suppurativa: implications for future investigations and therapeutic intervention. Exp Dermatol. 2021;30(6):820–830.
  • Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):999–1010.
  • Zouboulis CC, Benhadou F, Byrd AS, et al. What causes hidradenitis suppurativa?-15 years after. Exp Dermatol. 2020;29(12):1154–1170.
  • Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31.
  • Zee HH, Longcore M, Geng Z, et al. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020;34(5):1050–1056.
  • Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opin Drug Saf. 2020;19(4):381–393.
  • Blok JL, van Hattem S, Jonkman MF, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168(2):243–252.
  • Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994.
  • Kimball AB, Jemec GBE, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for Hidradenitis Suppurativa treatment. Br J Dermatol. 2014;171(6):1434–1442.
  • Ingram JR, Woo PN, Chua SL, et al. Interventions for Hidradenitis Suppurativa: a cochrane systematic review incorporating GRADE assessment of evidence quality. Br J Dermatol. 2016;174(5):970–978.
  • Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of Hidradenitis Suppurativa phenotypes: a multidimensional latent class analysis of the national italian registry IRHIS. J Invest Dermatol. 2020;S0022-202X(20):32184–32189.
  • Marzano AV, Genovese G, Casazza G, et al. Evidence for a ‘window of opportunity’ in Hidradenitis Suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol. 2021;184(1):133–140.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.